Alto Neuroscience, Inc.
ANRONYSEHealthcare● Active
$18.13
$-0.13(-0.71%)
Market Cap$636253103
P/E Ratio—
52W High$28.441
52W Low$2.15
Alto Neuroscience, Inc. (ANRO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANRO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.80
Est. -$0.56 · -42.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
ANRO reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.75 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.56 | -$0.80 | -42.9% | — | — | — |
| ▲ Q1 FY2026 | Mar 16, 2026 | -$0.56 | -$0.45 | +19.6% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.66 | -$0.52 | +21.2% | — | — | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$0.57 | -$0.65 | -14.0% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.59 | -$0.53 | +10.2% | — | — | — |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.65 | -$0.56 | +13.8% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.67 | -$0.62 | +7.5% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.75
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.80
EPS Est.
-$0.56
EPS Surpr.
-42.9%
Revenue
—
Q1 FY2026
Mar 16, 2026Beat
EPS Actual
-$0.45
EPS Est.
-$0.56
EPS Surpr.
+19.6%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.52
EPS Est.
-$0.66
EPS Surpr.
+21.2%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$0.65
EPS Est.
-$0.57
EPS Surpr.
-14.0%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.53
EPS Est.
-$0.59
EPS Surpr.
+10.2%
Revenue
—
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.56
EPS Est.
-$0.65
EPS Surpr.
+13.8%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.62
EPS Est.
-$0.67
EPS Surpr.
+7.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q3 FY2027 | $-0.72 | $-0.72 | $-0.72 | 1 |
| Q2 FY2027 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q1 FY2027 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q4 FY2026 | $-0.75 | $-0.75 | $-0.75 | 1 |
| Q3 FY2026 | $-1.10 | $-0.74 | $-0.57 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -42.9% | $24.63 | $22.85 | -7.23% |
| ▲ Q1 FY2026 | Mar 16, 2026 | +19.6% | $22.26 | $24.29 | +9.12% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +21.2% | $13.40 | $14.20 | +5.97% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -14.0% | $3.18 | $3.13 | -1.57% |
| ▲ Q2 FY2025 | May 14, 2025 | +10.2% | $2.37 | $2.20 | -7.17% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +13.8% | $2.80 | $2.69 | -3.93% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +7.5% | $4.84 | $4.50 | -7.02% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +15.5% | $8.22 | $8.98 | +9.25% |
Q2 FY2026-7.23%
Report Date
May 13, 2026
EPS Beat/Miss
-42.9%
Price Before
$24.63
Price After
$22.85
Q1 FY2026+9.12%
Report Date
Mar 16, 2026
EPS Beat/Miss
+19.6%
Price Before
$22.26
Price After
$24.29
Q4 FY2025+5.97%
Report Date
Nov 12, 2025
EPS Beat/Miss
+21.2%
Price Before
$13.40
Price After
$14.20
Q3 FY2025-1.57%
Report Date
Aug 13, 2025
EPS Beat/Miss
-14.0%
Price Before
$3.18
Price After
$3.13
Q2 FY2025-7.17%
Report Date
May 14, 2025
EPS Beat/Miss
+10.2%
Price Before
$2.37
Price After
$2.20
Q1 FY2025-3.93%
Report Date
Mar 20, 2025
EPS Beat/Miss
+13.8%
Price Before
$2.80
Price After
$2.69
Q4 FY2024-7.02%
Report Date
Nov 12, 2024
EPS Beat/Miss
+7.5%
Price Before
$4.84
Price After
$4.50
Q3 FY2024+9.25%
Report Date
Aug 13, 2024
EPS Beat/Miss
+15.5%
Price Before
$8.22
Price After
$8.98
Avg Beat Reaction+1.04%
Avg Miss Reaction-4.40%
Beat Rate6 / 8 quarters
Largest Move+9.25% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANRO ends December
Alto Neuroscience, Inc. (ANRO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.80 — missing the analyst consensus of $-0.56 by -42.9%. The next ANRO earnings date is expected around September 1, 2026.
Each quarter, investors track ANRO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANRO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANRO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANRO earnings · 5 questionsAlto Neuroscience, Inc.'s next earnings report is expected around September 1, 2026. ANRO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANRO historically reports after market close (AMC).
ANRO earnings datewhen is ANRO earningsANRO next earnings datewhen does ANRO report earningsANRO earnings calendar
▸ Source: FMP · Alto Neuroscience, Inc. SEC filings · US GAAP · Alto Neuroscience, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026